Can Warner Chilcott Run Up The Scores On Generics?
This article was originally published in The Pink Sheet Daily
Executive Summary
Success of petition seeking to block single-scored generics of Doryx will likely rest on the brand firm's ability to make a safety and efficacy case for its dual-scored version of the antibiotic, which may be difficult given that it was marketed as a single-scored tablet for so long.
You may also be interested in...
FDA Takes Its Tablet-Scoring Guidance To An Advisory Committee
On Aug. 9, FDA’s Pharmaceutical Science and Clinical Pharmacology panel will discuss the agency’s year-old draft guidelines on the data needed to support functional scoring of tablets. Issues related to tablet scoring as a purported strategy for delaying generic entry are at the heart of Mylan’s recent lawsuit against Doryx marketer Warner Chilcott.
Warner Chilcott Mum On Potential Suitors
Warner Chilcott didn’t address the elephant in the room – a potential acquisition – during its first quarter earnings call.
FDA Referees Tablet Scoring Skirmish: Brand And Generic May Have Different Lines
FDA denied Warner Chilcott’s citizen petition requesting the agency not approve ANDAs referencing Doryx unless they were for dual-scored tablets; Mylan must make change from single-score in its second manufacturing run.